ABSTRACT
The importance of the progesterone receptor (PR) in female reproductive and mammary gland biology is well recognized; however, the coregulators selectively enlisted by PR have yet to be comprehensively defined in vivo. To evaluate the involvement of steroid receptor coactivator (SRC)/p160 family members in these physiological systems, a mouse model (PR Cre/+ SRC-2 flox/flox ) was generated in which SRC-2 function was ablated specifically in cell-types that express the PR. Although PR mammary gland establishes an important role for mammary SRC-2 in cellular proliferative programs that require PR. Finally, the observation that SRC-2 is also expressed in many of the same cell-types in the human, underscores the importance of further study of this coregulator's role in both peri-implantation biology and mammary development.
INTRODUCTION

Progesterone action in vivo: insights from the mouse
For over a decade, studies on the progesterone receptor knockout (PRKO) mouse have established PR as a critical coordinator of female reproductive biology (1) . Removal of PR function not only undermined PRKO uterine function but severely compromised the ability of the hypothalamo-pituitary-ovarian axis to operate normally. Outside the female reproductive axis, the PRKO was instrumental in underscoring the importance of the P signal to mammary epithelial cell-division, a prerequisite for parity-induced mammary morphogenesis.
Moreover, absence of mammary PR rendered the PRKO significantly less susceptible to mammary tumorigenesis (2-4), supporting a bona fide role for PR in both mammary morphogenesis and tumorigenesis. Importantly, these observations confirm a number of past experimental studies using the rodent model (5) (6) (7) (8) , human observational investigations (9) (10) (11) , as well as recent clinical trials (12, 13) .
Despite over a decade of PRKO studies, two important questions have yet to be comprehensively addressed: (1) what are the molecular pathways and networks which mediate the P signal to an appropriate physiological response in each target tissue? And (2) which coregulators (whether they be coactivators or corepressors) are preferentially recruited by PR to modulate these downstream pathways? Although some advancement has been achieved to codify the transcriptome regulated by PR in some murine target tissues (for example, the uterus (14) (15) (16) (17) (18) (19) (20) ), disclosing the key coregulators selectively utilized in PR mediated physiological responses is only now being achieved due in large part to the recent development of inventive genetic methods applied to the mouse.
The SRC/p160 family of coactivators
Past in vitro investigations revealed that PR transactivation is dependent on direct interactions with members of the steroid receptor coactivator (SRC/p160) gene family (21) . The SRC family comprises three members: SRC-1 (ERAP140/ERAP160/NcoA-1), SRC-2 (TIF-2/GRIP-1/NcoA-2) and SRC-3 (p/CIP/RAC3/AIB1/TRAM-1/ACTR/NcoA-3); reviewed in (22). Sharing strong sequence homology, each of the three coactivators have been shown to directly bind the ligand binding domain of PR to enhance the transactivational potency of this nuclear receptor in the presence of ligand.
Knockout (KO) mouse models for each SRC member have recently been used to determine whether one or more SRC family members are required for physiological processes that depend on PR function. While the SRC-1KO survived to adulthood, its uterus was shown to undergo only a partial decidual response (23) , supporting an important role for SRC-1 in uterine functional changes that require PR. Importantly, the partial decidual response of the SRC-1KO uterus implied additional coregulators are needed along with SRC-1 to achieve a full decidual response. Retarded ductal elongation and dichotomous branching in the mammary gland of the pubescent SRC-1KO female suggested SRC-1 may also be required for mammary morphogenetic effects that depend on estrogen (E) signaling (23) .
Although a uterine defect was not detected in the SRC-3KO mouse (24) , the SRC-3KO mammary gland exhibited a partial impairment in parity-induced ductal side-branching and alveologenesis, a mammary phenotype that parallels to some extent the PRKO mammary defect (1) . Similar to the PRKO (2), the SRC-3KO mammary gland is significantly more resistant to mammary tumorigenesis (25) which indicates that mammary SRC-3 may be selectively recruited by a subgroup of PR-mediated transcriptional programs required for P-induced mammary morphogenesis and tumorigenesis. In aggregate, the SRC-KO studies suggest that SRC-1 has evolved as an important coactivator for uterine PR function, whereas SRC-3 is mandatory for a subset of mammary PR mediated events; investigations using the PR activity indicator (PRAI) model provide further support for this proposal (26) .
Unlike KOs for SRC-1 and -3, the SRC-2KO (referred to as the Transcriptional Intermediary Factor 2 KO or TIF2 -/-from hereon) displays severe reproductive abnormalities in the both sexes (27) . The TIF2 -/-male is significantly subfertile with developmental defects in spermatogenesis. Initial study of the TIF2 -/-female disclosed a marked hypofertility phenotype resulting from placental hypoplasia. Subsequent studies have revealed that TIF2 -/-pups (male and female) are significantly underrepresented in litters from TIF2 +/-intercrosses (unpublished observations); TIF2 -/-females resulting from such crosses are infertile.
The overt reproductive phenotypes of the global KO for SRC-2-coupled with the recent observation that many of the murine cell-lineages that express PR also express SRC-2 (28)-suggested that SRC-2 may occupy a critical coactivator role in a subset of PR dependent physiological processes that are required for the maintenance of female fertility as well as for mammary morphogenesis and function. To address this proposal, an innovative PR Cre/+ SRC-2 flox/flox bigenic was created (28) by crossing the PR Cre/+ knockin (29) with the SRC-2 flox/flox model in which exon 11 encoding the nuclear receptor interacting domain (NID) is floxed to facilitate Cremediated excision (27) . Because the resultant PR Cre/+ SRC-2 flox/flox bigenic is designed to postnatally ablate SRC-2 specifically in cell lineages that express the PR(28) , the embryonic, male reproductive, and the more recently reported metabolic (30) phenotypes exhibited by the TIF2 -/-model are circumvented to enable evaluation of SRC-2's specific involvement in PR dependent transcriptional programs in the adult. -/-male which develops a severe hypofertility phenotype (27) . The difference in phenotypes between the two KO models reflects the cell-lineage specific nature of the SRC-2 KO mutation in the PR flox/flox SRC-1KO trigenic is incapable of exhibiting any sign of a decidual reaction. The inability of the trigenic uterus to mount a decidual response establishes SRC-1 and SRC-2 as coactivators that are necessary and sufficient in launching a complete P-induced decidual response. Importantly, the expression levels of uterine SRC-1 and -3 were not changed in the PR Cre/+ SRC-2 flox/flox further underscoring the critical importance of uterine SRC-2 alone in the development of the receptive and decidualized uterus ( Figure 1D ).
SRC-2 ABLATION IN MURINE PR POSITIVE
Progestin-dependent mammary morphogenesis requires SRC-2
The expression of SRC-2 in mammary PR positive cells (28) suggested that this coactivator may occupy a role in PR-mediated signaling that results in ductal side-branching and alveolar morphogenesis in the adult gland. This assumption was confirmed by the fact that the PR Cre/+ SRC-2 flox/flox mouse failed to exhibit mammary morphogenesis that is typical following a standard 3-week EP treatment regimen (Figure 2A-D) . As previously described for the PRKO phenotype, the underlying cause of the PR Cre/+ SRC-2 flox/flox mammary defect was an inability of its luminal epithelium to undergo proliferation in response to hormone exposure ( Figure 2E ). These results establish an obligatory role for SRC-2 function in PR mediated transcriptional programs that are required for mammary ductal side-branching and alveologenesis, morphological changes that usually occur with the onset of pregnancy.
RELEVANCE TO THE HUMAN
As previously reported (32) , the transactivational potency of human PR is markedly elevated with increasing levels of human SRC-2 ( Figure 3A) , supporting an important coactivator role for SRC-2 in progestindependent physiological responses in the human. Furthermore, immunohistochemistry reveals that SRC-2 is expressed in a subset of human steroid-responsive target tissues ( Figure 3B-F) . In human prostate ( Figure 3B ), SRC-2 expression is spatially confined to the epithelial compartment, a known target-site for androgen receptormediated signaling (33) (34) (35) . Of relevance to this review, SRC-2 immunoreactivity is evident in a subgroup of epithelial cells in the normal human breast ( Figure 3C and  D) ; like the murine gland (28), SRC-2 is not expressed in the stroma. The heterogeneous spatial expression pattern for SRC-2 in the human mammary epithelium mirrors SRC-2's spatial expression profile in the murine gland (28) in which SRC-2 colocalizes with PR expression. As a corollary, PR has also been shown to display a punctate pattern of expression in the human breast (36), whether SRC-2 and PR colocalize in the human breast remains to be addressed. Examining this issue will be important as separation of PR positive mammary epithelial cells from proliferating cells is now accepted as a conserved cellular arrangement shared by rodent and human mammary tissue that supports a paracrine mode of action for mammary PR in the normal breast, reviewed in (37) . Based on similar regional expression patterns for mammary SRC-2 and PR in the rodent and human in conjunction with the observation that SRC-2 ablation in the murine mammary gland results in a morphological defect akin to the PRKO suggests that SRC-2 may have an important role not only in PR's paracrine mode of action in the normal breast but also in an autocrine mechanism which has been proposed to explain aberrant steroid hormone signaling in a subset of rodent and human breast cancers, reviewed in (37).
The most conspicuous phenotype exhibited by the PR cre/+ SRC-2 flox/flox female is an infertility defect, which results from an inability to manifest a receptive uterus for embryo implantation (Figure 1) . Immunohistochemical investigations have shown that uterine SRC-2 and PR localize to identical cell-types in the murine uterus (28), supporting direct involvement of this coactivator in PRmediated signaling pathways that are mandatory for uterine cellular changes that are required for embryo implantation and subsequent decidualization. Although it is not clear whether SRC-2 exhibits similar effects in the human uterus, recent immunohistochemical studies clearly show that SRC-2 and PR are expressed in many of the same celltypes of the human uterus ( Figure 3G -F) that have been described for the mouse (28) . From a clinical perspective, recurrent implantation failure is now accepted as a key underlying factor that negates the establishment of a successful pregnancy (either by natural means or by assisted reproductive technologies (ART) (38) ). Although the information is currently sparse regarding the involvement of SRC-2 in the human endometrium, recent reports have described abnormal elevations in SRC-2 levels in endometrial biopsies from infertile women with polycystic ovarian syndrome (PCOS) as well as in a subset of endometrial cancers (39, 40) , suggesting a possible role for this coactivator in human endometrial disorders. Because of the common use of progestins in the management of female reproductive health, coupled with our recent finding that SRC-2 is as an essential coactivator for PR action in female reproduction, we believe SRC-2 could represent a new molecular marker in diagnostic reproductive medicine and/or a future intervention target for the treatment of gynecologic pathologies.
PERSPECTIVE
This review describes how state-of-the-art murine genetic approaches uncovered a critical coactivator role for SRC-2 in PR-mediated signaling in both the uterus and mammary gland, with attendant implications for this coactivator's influence in similar systems in the human. Noticeably distinct from SRC-1 and SRC-3, whose coactivator properties are primarily dedicated toward transcriptional responses in the uterus and mammary gland respectively, SRC-2 is shown to be an indispensable PR coactivator in both target tissues. Because identification of tissue-specific coregulators that are preferentially recruited by PR is now recognized as a prerequisite to further understanding why different target tissues exhibit different Human steroid hormone responsive tissues express SRC-2. Panel A shows that the increase in transactivational functionality of human PR-B is dependent on increased levels of human SRC-2 (red bars ± S.D.) in the presence of P; in the absence of ligand this increase is not observed (blue bars). As described previously (41), human PR-B; SRC-2 (both cloned into pCR3.1) and the luciferase reporter pGRE.E1b.LUC were transiently cotransfected into HeLa cells in the presence or absence of 10 -7 M R5020; results are expressed in relative light units (RLU). Panel B shows SRC-2 is expressed in the majority of epithelial cells of the human prostate (black arrow), an established cellular target for androgen receptor action (33) ; note: the stromal compartment scores negative for SRC-2 expression (blue arrow). Panel C shows a representative example of a normal type 1 terminal ductal lobular unit (TDLU) of the human breast in which SRC-2 expression is contained within the epithelial compartment (black arrow). Panel D is a higher magnification of the region indicated by the black arrow in panel C. Note that SRC-2 expression is confined to a subset of epithelial cells of the TDLU (black arrow indicates an epithelial cell scoring positive for SRC-2 expression whereas the red arrow highlights an epithelial cell which is negative for SRC-2 expression; blue arrow denotes a stromal cell which is negative for SRC-2 expression). The spatial pattern of mammary SRC-2 expression resembles that previously reported for ER-alpha and PR expression in the human breast (36) . Panels E and F show sections of the glandular epithelial compartment (with associated stroma) of the human endometrium stained for PR and SRC-2 expression respectively. Note that PR and SRC-2 are detected in nuclei of the same cell-types in the glandular epithelium and stromal compartment (black and blue arrows respectively). The red arrow in panels E and F highlights stromal cells that are negative for PR and SRC-2 expression respectively; scale bar in panel E applies to panel F. Endometrial biopsies were obtained by endometrial pipelle from normally cycling women, aged between 18-35 years, during the mid-secretory (luteal) phase of the menstrual cycle (days 20-24 which is based on the ideal 28 day cycle in which day 1 represents the first day of menstrual flow and day 14 the day of ovulation). Cycle phase was determined relative to the timing of the urinary luteinizing hormone (LH) surge. Human SRC-2 and PR immunohistochemical detection was performed by established methods previously reported by our group (28, 42) . With institutional review board approval, human tissue samples were obtained from Baylor College of Medicine affiliated hospitals. responses to progestins, we believe that continued studies of SRC-2 action in vivo are warranted to further illuminate this understudied but important area of endocrine research.
